Psychooncological brief therapeutic intervention for parents of adolescent and young adults (AYA) with hematological malignancies

Not Applicable

Recruiting

Conditions: maladaptive coping
C81-C96
Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Registration Number: DRKS00004259

Lead Sponsor: niversitätsklinik für Hämatologie und Onkologie

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 160

Inclusion Criteria

a)acute / chronic hematological malign illness situation (ICD-10-C-diagnosis)
AND / OR
b)outpatient / inpatient treatment
c)ECOG Performance Status = 2
d)Patients 18. – 40. year of age
e)acceptable german language
f)acceptable cognitive abilities for understanding of diagnosis and treament
g)written and verbal study information
h)written informed consent

Exclusion Criteria

a. treatment mortality
b. oral intake of strong sedative or psychotropic medication
c. organic brain syndrome

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
adaptive and problem-oriented coping assessed with the adaptive subscales of Brief COPE questionnaire.<br>Measuring points: t0 (baseline), t1 (pre-treatment), t2 (post-treatment), t3 (follow-up, oncological end of treatment, max. 3 months after t0).<br>

Secondary Outcome Measures

Name	Time	Method
a. maladaptive coping assessed with the maladaptive subscales of the Brief COPE questionnaire<br>b. problems in parental coping/mastery assessed with the subscales coping/mastery and personal negative impact of the FaBel (Familien-Belastungs-Fragebogen/ Impact on Family Scale)<br>c. depressive symptoms (PHQ-D)<br>d. health-related quality of life (SF-36)<br><br>further secondary endpoints:<br>e. subjective illness concepts (Brief IPQ)<br>f. helping alliance scales patient/therapist (HAQ)<br>g. subjective prognosis estimation (one item as 6-ary visual analogue-scale)<br>Measuring points: t0 (baseline), t1 (pre-treatment), t2 (post-treatment), t3 (follow-up, oncological end of treatment, max. 3 months after t0).<br>